Core Insights - Rhythm Pharmaceuticals presented four data presentations at ObesityWeek® 2025, showcasing the efficacy of setmelanotide in treating acquired hypothalamic obesity [1][2][5] Company Overview - Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, with its lead product, setmelanotide (IMCIVREE®), approved for treating obesity related to specific genetic conditions [6][9][10] Clinical Data Highlights - Setmelanotide demonstrated a mean placebo-adjusted BMI reduction of 27.1% in patients receiving concomitant GLP-1 therapy and a 19.0% reduction in patients treated with setmelanotide alone [8][7] - Significant improvements in cardiometabolic health were observed in patients treated with setmelanotide, including better blood pressure and lipid levels [3][7] - Patient-reported outcomes indicated meaningful changes in hunger, weight, energy levels, and physical activity among participants in the TRANSCEND trial [2][3] Research Presentations - Dr. Christian Roth presented findings on the robust efficacy of setmelanotide in reducing BMI compared to previous anti-obesity treatments [2] - A poster by Dr. Jennifer Miller highlighted significant improvements in cardiometabolic parameters associated with setmelanotide treatment [3] - Dr. Roohi Kharofa's research focused on hyperphagia and genetic variants in early-onset obesity, involving data from 212 participants [4]